Once more, Britain has proven itself a powerhouse of scientific innovation, this time in the vital field of biotechnology.
A pioneering technology developed at the University of Kent, and now available for commercial use, stands ready to slash the costs of producing proteins used in everything from diagnostics to life-saving cancer therapeutics.
The breakthrough is the result of a homegrown collaboration between Kent scientists and the Science and Technology Facilities Council’s Central Laser Facility (CLF), a partnership that has, once again, demonstrated the strength of Britain’s world-class research infrastructure.
A British Solution to a Global Problem
At the heart of this achievement is the Vesicle Nucleating Peptide (VNp) technology, the intellectual foundation of Kent spin-out company Sirius Proteins. This ingenious innovation dramatically increases the yield, simplicity, and scope of recombinant protein production in bacteria, with applications spanning early-stage research, drug development, diagnostics, food production, and environmental management.
Recombinant proteins, the kind found in hormone treatments, vaccines, and even some washing powders, are produced by bacteria that have been genetically modified to manufacture them. Yet many of these proteins remain difficult and costly to produce, owing to instability, toxicity to the host cells, or the need for complex folding to stay functional.
It is here that British scientific ingenuity, in the form of Professor Dan Mulvihill and his team at Kent’s School of Natural Sciences, has provided the answer. Their technology directs bacterial cells to package recombinant proteins into membrane-bound vesicles and export them from the cell, vastly increasing production while simplifying purification, improving stability, and reducing costly downstream processing.
Cutting Costs, Speeding Cures
Dr Bree Streather, a former Kent PhD student who led the imaging work at the Laser for Science Facility (LSF), explained that the technology is especially valuable for producing insoluble proteins, such as insulin, which would otherwise clump together inside the cell, or proteins so toxic they would destroy their bacterial hosts before they could ever be isolated. By delivering these proteins intact, sometimes straight to their therapeutic target, the process becomes markedly simpler and more effective, promising to speed up drug production, ease pressure on the medical supply system, and, crucially, bring down the cost of medicines for patients here at home and abroad.
Professor Mulvihill was clear about the significance of the achievement, and generous in his praise for Britain’s national research facilities, saying the work with the CLF team had allowed his lab to demonstrate the technology’s applications in high-throughput protein engineering, screening, and drug discovery, as well as in producing functional monoclonal antibodies fit for research, diagnostic, and therapeutic use.
World-Leading British Facilities Prove Their Worth
The project drew on the world-leading, quantitative imaging techniques developed at the OCTOPUS Laser for Science Facility in Harwell, Oxfordshire, a further reminder of the calibre of scientific infrastructure Britain continues to build and sustain. Using these tools, the Kent-led team, working alongside Professor Lin Wang and Professor Stanley Botchway, set out to understand the structure and properties of the vesicles produced by their engineered bacteria.
The results, published in the respected Journal of Extracellular Vesicles, exceeded expectations. When compared with naturally occurring vesicles, those engineered using VNp technology proved considerably stronger in both composition and functionality, confirming the platform’s potential for extracellular vesicle engineering, targeted protein delivery, and future therapeutic development.
From British Lab Bench to Global Market
Professor Mulvihill described the achievement as the transformation of “a serendipitous biological observation into a versatile biotechnology platform with clear commercial relevance.” He added that the technology holds the promise of making protein production dramatically cheaper for industry and researchers alike, in his words, democratising protein production and opening the door to more affordable research and healthcare, both in Britain and around the world.
Professor Stan Botchway of the LSF CLF praised the project as a model of how Britain’s national facilities can support the journey from basic research to industrial application and clinical use, and welcomed the opportunity to help Sirius Proteins, and the wider field, continue to grow.
The commercial stakes are considerable. The global market for this technology is estimated at between $229 million and $1.74 billion, with strong projected growth, a market in which British science, once again, finds itself leading the way.
